Menu

Improved Risk Management: Benefits of Predefined Quality Tolerance Limits

Certain events in a study will occur that may impact interpretation of key efficacy or safety endpoints. Establishing appropriate quality tolerance limits (QTLs) can help identify and mitigate the frequency and extent of such event occurrences early. Creating QTLs ensures the early placement of risk mitigation steps to avoid the risk of key study-level parameters or events exceeding the established tolerance limits at the end of the study.

In this white paper, learn how PPD has established a robust and well-integrated, cross-functional process to help its sponsors execute the QTL component of ICH E6 (R2) that includes clinicians, data analytics, statisticians and other disciplines involved in clinical trial design, conduct and final reporting.

Rakhi Kilaru
Rakhi Kilaru
Olgica Klindworth
Olgica Klindworth

To download the white paper, please complete the form below. Fields marked with * are required.


Pharmaceutical Product Development, LLC and its affiliates (together “PPD”) will use the information you provide on this page for the purpose of contacting you on this subject. Important information on how PPD handles personal data and what rights you may have under data privacy laws are included within PPD’s Global Privacy Policy.

Improved Risk Management: Benefits of Predefined Quality Tolerance Limits

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2018 Pharmaceutical Product Development, LLC. All rights reserved.